Does Interrupting Self-Induced Lung Injury and Respiratory Drive Expedite Early Spontaneous Breathing in the Setting of Early Severe Diffuse Acute Respiratory Distress Syndrome?

Competing Interests: Dr. Quintin received honoraria and unrestricted research grants from Boehringer-Ingelheim, France, UCB Pharma, Belgium, and Abbott International, Chicago, IL (1986–1996) and holds U.S. Patent 8 703 697: Method for treating early severe diffuse acute respiratory distress syndrome; he disclosed the off-label product use of dexmedetomidine and clonidine. Dr. Constantin reports personal fees and nonfinancial support outside of the submitted work from Dräger, GE Healthcare, Sedana Medical, Baxter, and Ammoed; personal fees from Fisher and Paykel Healthcare, Orion, Philips Medical, and Fresenius Medical Care; and nonfinancial support from LFB and Bird Corporation. The remaining authors have disclosed that they do not have any potential conflicts of interest.